This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Data can be available upon request to the corresponding author.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44. https://doi.org/10.1056/NEJMoa1707447.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331–42. https://doi.org/10.1056/NEJMoa1914347.
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491–502. https://doi.org/10.1016/s0140-6736(21)01222-8.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2018;380:45–56. https://doi.org/10.1056/NEJMoa1804980.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52. https://doi.org/10.1016/s0140-6736(20)31366-0.
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48. https://doi.org/10.1056/NEJMoa1709866.
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2116133.
Majhail NS, Nayyar S, Santibañez ME, Murphy EA, Denzen EM. Racial disparities in hematopoietic cell transplantation in the United States. Bone Marrow Transpl. 2012;47:1385–90. https://doi.org/10.1038/bmt.2011.214.
Tao L, Foran JM, Clarke CA, Gomez SL, Keegan TH. Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood. 2014;123:3553–62. https://doi.org/10.1182/blood-2013-07-517110.
Griffiths R, Gleeson M, Knopf K, Danese M. Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer. 2010;10:625 https://doi.org/10.1186/1471-2407-10-625.
Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2011;117:2530–40. https://doi.org/10.1002/cncr.25765.
Peravali M, Gomes-Lima C, Tefera E, Baker M, Sherchan M, Farid S, et al. Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses. World J Clin Oncol. 2021;12:103–14. https://doi.org/10.5306/wjco.v12.i2.103.
We would like to acknowledge all the physician assistants and nurses on the bone marrow transplant and cellular therapy unit for their compassionate care for these patients. These studies were supported by grants from Izzy Englander, Jane and Myles Dempsey Family, Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program and the Leukemia and Lymphoma Society.
AV has received research funding from Prelude, BMS, GSK, Incyte, Medpacto, Curis and Eli Lilly and is a scientific advisor for Stelexis, Novartis, Acceleron and Celgene and received honoraria from Stelexis and Janssen and holds equity in Stelexis and Throws Exception. KG has received research funding from ionctura, SA and ADC therapeutics. AS has received honorarium from GLG, Guidepoint, Onclive, consultation fee from Janssen Pharmaceuticals, advisory board fee from Rigel Pharmaceuticals, research funding from Kymera Therapeutics. AT, MA, KP, RAS, NK, NS, IM, EF, SGL, RE, IB and MG have nothing to disclose.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Thakkar, A., Abreu, M., Pradhan, K. et al. Efficacy and safety of CAR-T cell therapy in minorities. Bone Marrow Transplant (2022). https://doi.org/10.1038/s41409-022-01670-1